Related Experiment Videos
Tumor markers for breast cancer
1Breast Evaluation Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
Summary
Identifying and validating breast cancer markers is crucial for patient care. Understanding marker utility, independence, and limitations ensures accurate diagnosis and effective treatment strategies.
Area of Science:
- Oncology
- Biomarkers
- Molecular Diagnostics
Background:
- Numerous antigenic and genetic markers have been investigated for breast cancer.
- Potential applications include identification, screening, prognosis, detection, and monitoring.
- Key markers in 1993 included BrCa1, p53, HER-2/neu, cathepsin-D, angiogenesis indicators, CA15-3, and CEA.
Purpose of the Study:
- To evaluate the clinical utility of various breast cancer markers.
- To determine marker independence and avoid redundancy.
- To inform clinicians about marker sensitivity and specificity limitations.
Main Methods:
- Review of proposed antigenic and genetic markers for breast cancer.
- Assessment of potential clinical applications and prognostic value.
- Consideration of marker independence and diagnostic accuracy.
Main Results:
- The precise clinical utilities of many proposed markers remain undetermined.
- Marker independence and limitations in sensitivity/specificity require careful evaluation.
- Judicious application of germ-line, tissue, and soluble markers is recommended.
Conclusions:
- Accurate assessment of breast cancer markers is essential for clinical decision-making.
- Understanding marker limitations prevents over- or under-interpretation.
- Effective use of validated markers can improve patient care for those at risk or diagnosed with breast cancer.